April 08, 2011
Horizant Approved for Restless Legs Syndrome
Horizant is a prodrug of gabapentin, which binds to a specific type of calcium channel but does not exhibit affinity for other common receptors. The exact mechanism of action of Horizant in treating moderate-to-severe primary RLS is unknown. Horizant is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles.
Horizant is expected to be available July 1, 2011 in a 600mg dosage strength.
For more information call (888) 825-5249 or visit www.gsk.com.